



NDA 21-055/S-002/S-003

Ligand Pharmaceuticals, Inc.  
Attention: James L'Italien, Ph.D.  
10275 Science Center Drive  
San Diego, CA 92121-1117

Dear Dr. L'Italien:

Please refer to your supplemental new drug applications dated January 5, 2001 (S-002) and April 27, 2001 (S-003), received January 8, 2001 and April 30, 2001 respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Targretin<sup>®</sup> (bexarotene) capsules, 75 mg.

We acknowledge receipt of your submission dated May 16, 2001 amending supplement 002 and your February 10, 2000 submission of final printed labeling for the NDA. This FPL has been superseded and will be retained in your file.

These "Changes Being Effected" supplemental new drug applications provide for additional safety information to be added to both the package insert and the patient package insert regarding data that suggests concomitant administration of Targretin<sup>®</sup> capsules during tamoxifen therapy is associated with moderate reduction in plasma tamoxifen concentrations.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter for use as recommended in the agreed-upon labeling text and with the minor editorial revisions indicated in the enclosed labeling.

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the enclosed labeling (text for the package insert, text for the patient package insert). These revisions are terms of the approval of these applications.

Please submit FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount tent of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 21-055/S-002, S-003." Approval of these submissions by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Amy Baird, Regulatory Project Manager, at (301) 594-5779.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.  
Director  
Division of Oncology Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Richard Pazdur

4/21/03 05:09:40 PM